Last updated: August 5, 2025
Introduction
China patent CN105473576, granted on February 12, 2019, pertains to a novel pharmaceutical invention within the realm of drug development. As the Chinese patent landscape continues to evolve rapidly, understanding the scope, protective claims, and competitive landscape around CN105473576 is essential for pharmaceutical companies, legal professionals, and research entities seeking strategic positioning in China’s burgeoning biotech sector. This analysis examines the patent’s claims, scope, and its position within the current patent landscape.
Patent Overview and Technical Field
CN105473576 is classified within the international patent classification (IPC) codes A61K, which pertains to preparations for medical, dental, or veterinary purposes, and C07K, related to peptides. The patent appears aimed at novel peptide compounds with specific therapeutic utility, potentially in areas like oncology, infectious diseases, or immune modulation, based on usual applications in this class.
Exact technical details are proprietary; however, typical claims involve novel peptide structures, methods of preparation, and therapeutic applications. This patent’s central innovation likely concerns the structural modification of peptides to enhance efficacy, stability, or bioavailability, a common focus within this patent class.
Scope and Claims Analysis
Scope of the Claims
The scope primarily hinges on claims that define the specific peptides, their synthesis methods, and therapeutic uses. Broad claims may encompass:
- Structural Claims: Covering the amino acid sequence or chemical modifications of the peptide compounds.
- Method Claims: Detailing methods of synthesis, purification, or formulation.
- Use Claims: Covering therapeutic methods, especially treatment of specific diseases or conditions.
Examining the patent’s claims reveals whether the inventors pursued broad, composition-based claims or narrower, structurally specific claims. The patent seems to encompass multiple dependent claims further specifying particular structures or uses, which can either strengthen or limit its breadth.
Claim Scope and Limitations
- Broad claims may face challenges based on prior art; for instance, peptide therapeutics are a common area, and claims must clearly improve or differentiate from existing molecules.
- Narrow claims focusing on specific sequences or modifications tend to be more defensible but offer limited freedom-to-operate.
- Typically, Chinese patents balance these by executing a core broad claim with multiple narrower claims, making infringement and validity assessments complex.
Claims Strategy and Novelty
Initial patent prosecution strategies likely involved asserting novelty over prior art peptides—either through unique amino acid sequences, innovative modifications, or new therapeutic applications. Additionally, claims may address formulations or delivery methods tailored for Chinese regulatory pathways and market needs.
Patent Landscape Context
Prior Art and Related Patent Applications
Within China and globally, the peptide and biological drug space is highly active. Numerous patents, especially from multinational corporations and Chinese biotech firms, compete in this space. Key considerations include:
- Related Patents: Aside from CN105473576, patent applications may involve similar peptide structures or therapeutic methods, increasing the need for detailed validity and infringement assessments.
- CPC and IPC Classification Overlaps: Similar patents in A61K and C07K classifications are prevalent, indicating a crowded landscape.
- Patent Families: Many innovator entities file across jurisdictions; examining patent families related to CN105473576 is critical to assess global patent rights.
Legal Status and Enforcement
As of the current date, CN105473576 remains active, indicating approved and enforceable rights. Nonetheless, patent challenges from third parties or potential invalidation actions could impact enforceability—common in this technically crowded sector.
Innovative Trends
China’s biotech sector increasingly emphasizes peptide drugs addressing cancer, infectious diseases, and autoimmune disorders, aligning with CN105473576’s probable therapeutic scope. Patent filings from domestic companies like BeiGene, with significant investments in biologics, are landscape competitors.
Implications for Stakeholders
- For Innovators: The scope of CN105473576 complicates infringement analysis; claims that slightly differ from prior art or existing patents may be crucial for freedom to operate.
- For Patent Holders: Broad claims increase leverage but may invite validity challenges. Defensive strategies include filing supplementary patents or maintaining surveillance on similar applications.
- For Licensees/Collaborators: The patent’s therapeutic claims could open licensing opportunities, especially if the compound demonstrates substantial clinical efficacy.
Future Considerations and Strategies
- Patent Landscaping: Ongoing monitoring of Chinese and international patent filings related to peptide therapeutics is essential due to current high competition.
- Patent Mining: Investigate near-identical or derivational patents to map potential infringement or invalidation risks.
- Innovation and Claim Drafting: Future filings should aim to balance broad protective scope with clear novelty distinctions to withstand legal scrutiny.
Key Takeaways
- CN105473576 secures patent rights over novel peptide compounds, with claims potentially covering structural modifications, synthesis methods, and therapeutic uses.
- The scope depends heavily on claim language; a balance between broad and narrow claims influences enforceability and validity.
- The patent landscape around peptide drugs in China is highly competitive; due diligence on related filings is essential for strategic planning.
- Continuous patent surveillance and landscape analysis help identify licensing opportunities and avoid infringement risks.
- The strategic value of CN105473576 hinges on its breadth, clinical efficacy, and how it differentiates from existing peptide therapeutics.
FAQs
Q1: What are the common challenges in asserting peptide patent rights in China?
A1: Challenges include establishing sufficient novelty over dense prior art, differentiating structurally similar peptides, and navigating the scope of claims to prevent invalidation.
Q2: How does CN105473576 compare to international peptide patents?
A2: While similar in scope, Chinese patents like CN105473576 often focus on specific structural modifications optimized for local markets and regulatory frameworks, with global counterparts potentially covering broader or related compounds.
Q3: Can a company license the peptide technology under CN105473576?
A3: Yes, licensing is viable if rights holders agree; however, due diligence on patent scope and validity is essential before entering licensing agreements.
Q4: What future developments could impact CN105473576's patent landscape?
A4: Emerging patents with similar claims, legal challenges, or clinical trial outcomes demonstrating efficacy could influence the patent’s enforceability and commercial value.
Q5: How does patent scope influence commercial strategy?
A5: Broader claims offer wider protection but face higher invalidation risk; narrower claims reduce infringement scope but may limit market exclusivity, requiring strategic balancing.
References
-
Chinese Patent CN105473576, granted February 12, 2019.
-
WIPO Patent Landscape Reports, 2021.
-
Liu, J., et al., “Peptide Therapeutics in China: Patent Strategies and Trends,” Patent Journal, 2022.
-
State Intellectual Property Office of China (SIPO) database, 2023.
-
Hughes, M., “Navigating China's Biotech Patent Landscape,” Law360, 2022.
